Loading...
Attractive Dividend Yield: Pfizer offers a high dividend yield of 7.2%, significantly higher than the S&P 500 and average pharmaceutical stocks, making it appealing to dividend investors.
Patent Cliff Concerns: The company faces a patent cliff with key drugs losing protections in 2027 and 2028, which raises concerns about its ability to sustain its dividend amidst potential revenue declines.
Acquisition Strategy: Pfizer's recent acquisition of Metsera for a promising weight loss drug highlights its proactive approach to strengthening its drug pipeline in response to competitive pressures.
Historical Dividend Cuts: Pfizer has a history of adjusting its dividend, including a cut in 2009 after acquiring Wyeth Pharmaceuticals, indicating potential risks for investors relying on dividend stability.
